Agree it's a powerhouse team and backing, but HRS9531 (Kailera's lead program) isn't even close to best-in-class. Based on the human clinical data so far it'll be 4th place when approved, and competing with a better generic by 2032.

Congrats to Xuefeng and the authors on a great paper.
academic.oup.com/sleep/advanc...

Sometimes things do line up between species